$10 Billion Deal, page-86

Our main focus now is on finding a commercial partner for the HIV programme.  While we are designing what the next trial would look like we at this point do not anticipate running that trial ourselves, we would like to have one of the big pharma in there with us funding that and developing it in parallel, that’s really our prime focus.  Certainly, having a bit more money in the bank from the exercise of these options puts us in a reasonably strong position to get to that negotiation period.  We still are doing some additional work, in particular with Hepatitis C to identify a need and to progress that, a really fascinating and really very valuable programme that we’ve not really spent a lot of money on to date as we’ve been focussed on our lead programme, but it’s in the interest of shareholders for us to really add some additional value in some of these early stage programmes because there is a possibility of early stage deals for things like Hepatitis B.